Re: vicki

November 4, 2000

Vicki and Rosemary,

Do you have the exact address for the database? Rosemary you said this was

coming from the, " Investigational Drugs Database. " What is the address ?

Sally

<< I'm sure Anne's oncologist would be familiar with this upcoming

symposium...

here's an abbreviated list of selected drugs. If not, get another

one...(oncologist that is).

I can't access the complete database.

After symposium it would be good to get a copy of proceedings, reports,

full drug list etc. We need someone with access to the Investigational Drugs

Database, which is where this comes from. >>

November 4, 2000

Vicki and Rosemary,

Do you have the exact address for the database? Rosemary you said this was

coming from the, " Investigational Drugs Database. " What is the address ?

Sally

<< I'm sure Anne's oncologist would be familiar with this upcoming

symposium...

here's an abbreviated list of selected drugs. If not, get another

one...(oncologist that is).

I can't access the complete database.

After symposium it would be good to get a copy of proceedings, reports,

full drug list etc. We need someone with access to the Investigational Drugs

Database, which is where this comes from. >>

November 4, 2000

on 5/11/00 1:50 AM, GospelBlessings@... at GospelBlessings@...

wrote:

> Vicki and Rosemary,

>

> Do you have the exact address for the database? Rosemary you said this was

> coming from the, " Investigational Drugs Database. " What is the address ?

>

> Sally

>

> << I'm sure Anne's oncologist would be familiar with this upcoming

> symposium...

> here's an abbreviated list of selected drugs. If not, get another

> one...(oncologist that is).

>

> I can't access the complete database.

> After symposium it would be good to get a copy of proceedings, reports,

> full drug list etc. We need someone with access to the Investigational Drugs

> Database, which is where this comes from. >>

>

Sally,

the address is http://drugnet.com.

This is a worldwide database for competitor intelligence on R and D.

We need someone with a subscription to gain full access.

Go to news, headlines. and also go to archives.

Here is the last cancer drug meeting synopsis:

Summary of the American Association for Cancer Research 91st Annual Meeting

1-5 April 2000, San Francisco, CA, USA

Authored by Hannah Brown and Charlotte Worker, Current Drugs Ltd, London, UK

Current Drugs editors Charlotte Worker and Hannah Brown attended the

American Association for Cancer Research (AACR) 91st Annual Meeting held in

San Francisco from 1 to 5 April 2000. The meeting was the largest in the

association's history; delegates numbered over 7500, and the volume of work

presented had increased by 19% since 1999. The purpose of the meeting was to

present the most timely and significant research results in all the

scientific disciplines related to cancer. The program included ten special

lectures and one plenary session (consisting of five plenary lectures); 28

symposia; 12 educational sessions; 46 meet-the-expert sessions; 38

mini-symposia; 36 poster discussion sessions; and, 231 poster sessions. This

meeting produced many new therapeutic leads, and 43 novel compounds were

added to the database. In addition, new developmental information was

disclosed for many compounds and 329 records were updated as a direct

result. To date, Current Drugs has published 19 conference reports from this

meeting, including daily reports from the attending editors and commissioned

reports by experts in their respective fields [361378], [361403], [361408],

[361430], [361468], [361542], [361664], [361727], [362062], [362063],

[361854], [363482], [362917], [363317], [363762], [363552], [363616],

[363708], [363898].

Selected new drugs added to the IDdb

Apoptosis stimulators

BH3 mimetics

Biomeasure Inc, along with the Institut Henri Beaufour and University

College Cork, has synthesized and is investigating a number of small

anticancer peptides designed to mimic the BH3 domain of pro-apoptotic Bcl-2

family members, such as Bak and Bax.

It was found that prostate tumor cells underwent apoptosis when they were

cultured with these peptides. The mimetics were shown to block the

association between Bak and Bcl-2.

FB-642

FB-642 is an apoptosis inducer which is under development by The Procter &

Gamble Co. This agent has completed phase I trials in adults with advanced

malignancies.

A preclinical study evaluated the antitumor activity of FB-642 in eight

human tumor xenograft models, including HT-29 colon, MCF-7 and MX-1 breast,

SK-MES lung and MiaPaCa pancreatic tumors. Using various dosing regimens,

the agent caused > 58% inhibition of these tumors. Significant toxicity was

seen with doses upwards of 6000 mg/kg. As of April 2000, three studies were

ongoing under sponsorship from Procter & Gamble, the results from which are

due to be presented at the American Society of Clinical Oncology Annual

Meeting in May 2000.

PX-12

ProLX Pharmaceuticals LP is investigating

1-methylpropyl-2-mercaptoimidazolyl disulfide, or PX-12. This inhibitor of

thioredoxin may have potential in the treatment of cancer, and is scheduled

to enter phase I trials during 2000.

PX-12 stimulates apoptosis and displays excellent antitumor activity in

human MCF-7 breast, A549 lung and HL60 tumor xenografts in mice. The agent

is able to irreversibly block the cell cycle at the G2/M interphase in MCF-7

and tsFT210 cells, which occurred without affecting the phosphorylation

status of the cyclin-dependent kinase Cdk2. PX-12 administered ip to mice at

the MTD, ie, 30 mg/kg and four times daily at 25 mg/kg, resulted in no

histopathological effect on tissues, blood chemistries, white blood cells,

platelets or bone marrow.

CDK inhibitors

PD-0183812

PD-0183812 is a potent and selective CDK4/cyclinD1 inhibitor that belongs to

a series of [2,3-d] pyridopyramidines under evaluation by Parke- & Co,

Onyx Pharmaceuticals Inc and the CRC Center for Cancer Therapeutics, as

potential treatments for Rb-positive tumors.

In in vitro studies, PD-0183812 inhibited purified CDK4 with an IC50 value

of 0.008 m M but showed 26- and > 5000-fold less activity against

CDK2/cyclinA and CDC2/cyclinB, respectively. Flow cytometry analysis showed

that Rb-positive tumor cells were arrested in G1 after treatment with

PD-0183812, whereas Rb-negative cells continued to cycle.

GW-8510, GW-2059 and GW-5181

These compounds are part of a series of novel substituted oxindole

inhibitors of the cyclin dependent kinases (CDKs). The series is under

investigation by Glaxo Wellcome plc, Pfizer Inc and Hoffmann-La Roche Inc,

for the potential treatment of proliferative disorders, including

chemotherapy-induced toxicities such as alopecia, myelosuppression and

mucositis, in addition to standing alone as antitumor therapies.

The compounds were designed based on the X-ray crystallographic structure of

the CDK2-ATP binding site. Data presented at the conference, demonstrated

that these three lead compounds show a 10-fold selectivity for the

CDK2/cyclin A complex, against a panel of other CDKs. IC50 values for

GW-2059, GW-8510 and GW-5181 against the CDK2/cyclin A complex were 2.3, 10

and 7 nM, respectively.

SU-9516

SUGEN Inc and the Albert Einstein College of Medicine are collaborating on

the investigation of SU-9516, a 3-substituted, oxindole-based inhibitor of

CDK activity, for the potential treatment of cancer, specifically colon

tumors. SUGEN has developed a series of 3-substituted indoline-2-ones, which

are currently under evaluation for pharmacokinetic parameters, chemical and

metabolic stability, and in vivo efficacy.

A study demonstrating the antitumor activity of SU-9516 was presented at the

conference. Following treatment with SU-9516 for 24 h, an antiproliferative

effect was observed in both RKO and SW480 cell lines; in RKO cells this

effect was still evident 7 days after drug removal. The EC50 value for RKO

and SW480 cells was found to be 6.5 and 6 m M, respectively. In additional

experiments, the drug exposure time was altered and cell cycle phase

monitored, demonstrating the CDK-inhibitory activity of SU-9516 (IC50 = 22

nM).

Angiogenesis inhibitors

ER-68203-00

Eisai Co Ltd is investigating the angiogenesis inhibitor and potential

anticancer therapeutic, ER-68203-00. It is claimed that this compound may

have a novel mode of action in that it appears to modulate the level of

integrin a-2 expression. Furthermore, the anti-angiogenic profile of

ER-68203-00 appears to be unique when compared to other angiogenesis

inhibitors, eg, TNP-470 (Takeda Chemical Industries Ltd), SU-5416 (SUGEN

Inc) and marimastat (British Biotech plc).

Data have shown that ER-68203-00 is able to inhibit the proliferation or

tube formation of HUVEC cells, induced by either bFGF or VEGF (with the same

efficacy), in a rat aortic angiogenesis model. In addition, a down-regulate

in the expression of integrin a-2, -3 and -5 and b-1 on HUVEC cells is seen

following treatment with 0.05 m/ml of ER-68203-00 for 48 hours. Also, levels

of a-2 integrin mRNA, but not b-1, decreased with drug treatment (0.05

m/ml), whilst a-2 integrin expression on the cell surface remained unchanged

in normal cells with 0.5 m/ml treatment with the drug.

In human tumor xenograft models (eg, colon, pancreatic and breast), oral

ER-683203-00 showed antitumor effects when administered daily; at 100 mg/kg

the drug reduced tumor volume in the xenograft models without the appearance

of a resistant tumor over 3 months later. Also, in an orthotopic

transplantation model with KP-1 tumor cells, 200 mg/kg bid of the drug

prevented tumor growth, whilst also demonstrating inhibition of breast tumor

xenograft metastases of the lung and lymph node. ER-68203-00 was also active

against taxol-resistant tumor.

GFB-111

GFB-11i, designed and synthesized by Yale University and the H Lee Moffitt

Cancer Center and Research Institute, along with support from the National

Cancer Institute, is able to block PDGF-induced receptor autophosphorylation

and, therefore, may have potent anti-angiogenic and anticancer properties.

This compound achieves its effects through PDGF binding, with an IC50 value

of 250 nM. It also inhibits VEGF-induced Flk-1 tyrosine phosphorylation, and

Erk1/Erk2 activation with an IC50 value of 10 mM. In a nude mouse xenograft

model, using sc implanted human and rat cancer cells, resulted in

significant inhibition of tumor growth and angiogenesis was observed with

GFB-111 at 50 mg/kg/day ip.

Natural products

Bengamides

This group of compounds, under investigation by Novartis AG, comprise

cyclosporine derivatives isolated from Jaspindae sponges.

Bengamides have been evaluated in the NC160 cell line and show a unique

antitumor profile compared to standard antitumor agents. A subset of

bengamides has been further profiled for antitumor activity against the

MDA-MB-435 human breast carcinoma model in nude mice. In an additional study

presented at the meeting, bengamide E was investigated in order to identify

its mechanism of growth inhibition. It was found to arrest cells at the G1/S

restriction point and within the G2/M phase of the cell cycle. Novartis has

isolated an active analog and lead compound from this series, and expects to

commence clinical trials in May.

Sesquiterpenoids

Beta- and ar-tumerone are sesquiterpenoid compounds, isolated from an

extract of Curcuma zedoaria by Pacific Corp, which is examining the

potential of these compounds as anti-inflammatory and cancer chemopreventive

agents.

Beta- and ar-tumerone were shown to selectively suppress LPS-stimulated

COX-2 induction without direct inhibition of COX-2 activity. These compounds

are now being assayed for their effect on COX-2 transcription and

translation, and may provide the template for several leads.

Vaccines

Peptide GM-CSF/IL-2 vaccination therapy

The Medical University of South Carolina is investigating a

peptide-GM-CSF/IL-2 vaccination therapy, for which data was presented at the

conference.

This gel vaccine tackles a common problem that occurs in cytokine-enhanced

approaches to cancer therapy; applications of this technique, although

validated in clinical trials, are limited due to the difficulty in

maintaining elevated plasma cytokine levels and the toxic effect of

high-dose delivery. The presented study described vaccination with

OVA/GM-CSF/F2 gel, followed by injection of human recombinant IL-2 in an

immunologically inert form of the gel; the dose of IL-2 was 5-fold lower

than that used in clinical trials. The vaccine conferred effective

protection against initial and subsequent tumor challenge in mice.

Kline Beecham plc has shown interest in advancing this discovery to

clinical trials.

CEA-dendritic cell-based vaccine

Takara Shuzo Co Ltd is developing a dendritic cell-based vaccine, using

dendritic cells pulsed with a CEA epitope peptide. A phase I study of this

vaccine was presented at the conference.

Ten patients with solid tumors (seven with colorectal, two with lung and one

with gastric cancer) received at least five injections of 2 to 20 million

cells per injection at 2-week intervals, along with systemic administration

of IFN-a and TNF-a. The vaccine was not toxic, but the response rate was not

very encouraging. However, some patients showed a decrease in serum CEA

levels, and one had an immunological response.

ELVIS-neu

A potential breast cancer vaccine was described, composed of the rodent neu

protein, inserted into the novel plasmid, ELVIS, developed by Chiron Corp.

The MD Cancer Center, which is investigating this therapy, found

that when as little as 20 mg of ELVIS-neu was injected id into mice, a

humoral response was detected to mouse mammary tumor cells. Intranuscular

injection of 100 mg of ELVIS-neu three times at 2-week intervals, resulted

in a signifiant reduction in the incidence of injected mammary fat pad and

significantly fewer lung metastases compared to controls.

Gene therapies

ISIS-16609 and ISIS-16601

A series of 25 oligonucleotides, containing 2'-methoxyethyl substitutions

and a phosphorothioate backbone, have been synthesized by Isis

Pharmaceuticals Inc. The leads, ISIS-16609 and ISIS-16601, are 20-mer

antisense oligonucleotides and have been shown to have therapeutic potential

in treating tumors which express the WT1 gene, such as pediatric kidney

tumors and leukemias.

ISIS-16609 (to exon 5 of WT1), and ISIS-16601 (to the 3'-UTR of WT1) reduced

total WT1 RNA levels significantly, 5 h post-treatment, with a cocurrent

reduction in WT1 protein; ISIS-16609 achieved this reduction in a

dose-dependent manner at 1 to 10 mM.

AVI-4126

AVI BioPharma Inc is investigating a potential treatment for carcinoma: a

20-mer phosphorodiamidate morpholino oligomer, AVI-4126, which is antisense

to the c-myc RNA.

When 50 mM AVI-4126 was used to treat lung (LL) carcinoma cells in

vitro, viable cell number decreased by about 54%, and the levels of c-myc

protein were reduced. The in vivo antitumor effects of AVI-4126, when

administered for 7 days at 10 to 1000 mg/mouse/day, were dose-dependent up

to 200 mg/mouse/day, in mice with lung tumors, induced via injection of LL

cells. The drug was detected in tumor lysate 4 h following administration.

Further updates

Other drugs updated or added to the IDdb from this meeting include:

p21 gene therapy, AntiCancer (AntiCancer Inc); CT-052923 (COR Therapeutics

Inc); PEG-ara-c derivatives, Enzon (Enzon Inc); GSDI-126 (GenVec Inc);

TLC-144 (The Liposome Company Inc); Ro-31-7453 (Hoffmann-La Roche Inc);

NSC-678515 (National Cancer Institute); LG-190119 (Baylor College of

Medicine); LM-4108 (Vanderbilt University); LCS-640 (Yale University);

Peptide-doxorubicin-PEG conjugate ( Pharmaceuticals Inc); B7-1 gene

therapy (town University Medical Center); p53 peptide (Novartis AG);

SJG-136 (University College London); SP-1053C (Supratek Pharma Inc);

SB-238039 (Kline Beecham Pharmaceuticals [uS]); FC-2.15 (Universidad de

Buenos Aires); p53-hdm2 antagonists (Novartis Pharma AG); EPO-906 (Novartis

Pharma AG); p16/p53 gene therapy (HepaVec AG fuer Gentherapie); CEA-based

DNA vaccine (Lexigen Pharmaceutical Corp); bile acid derivatives (Pusan

National University); T12 (Chengdu DIAO Pharmaceutical Co); NSC-614491

(National Cancer Institute); peptidomimetic bradykinin antagonists

(University of Colorado at Denver); BMP-6 (Creative BioMolecules Inc);

S-23906-1 (Servier); pyroxamide (National Cancer Institute); MDL-73811

(Hoechst n Roussel Inc); MAb ICR-62 (Institute of Cancer Research UK);

S-1 (Taiho Pharmaceutical Co Ltd); conophylline (Terumo Corp); cell cycle

regulators (ONYX Pharmaceuticals Inc); ONYX-015 (ONYX Pharmaceuticals Inc);

cemadotin (Knoll AG); LY-309887 (Eli Lilly & Co); perillyl alcohol

(Wisconsin Alumni Research Foundation); SB-203580 (Kline Beecham plc);

cetuximab (ImClone Systems Inc); angiopoietins (Regeneron Pharmaceuticals

Inc); TZT-1027 (Teikoku Hormone Manufacturing Co Ltd); WMC-26 (National

Cancer Institute); IgG-RFB4-SMPT-dgA (National Cancer Institute); CGP-52608

(Ciba-Geigy International Ltd); Angiostatin (EntreMed Inc); SRL-172

(Stanford Rook Holdings plc); COL-3 (State University of New York Stony

Brook); GEM-231 (Hybridon Inc); HER-2 antagonists (SUGEN Inc); SU-5416

(SUGEN Inc); TJN-151 (Tsumura & Co Ltd); INX-3280 ( Jefferson

University); STI-571 (Novartis AG); fluasterone (Aeson Therapeutics Inc);

GMK (Memorial Sloan-Kettering Cancer Center); mitoxantrone (Immunex Corp);

ImmuRAID-LL1 (Immunomedics Inc); ZD-1839 (AstraZeneca plc); CRL-1005 (Vaxcel

Inc); geranylgeranyl transferase inhibitors (University of Pittsburgh);

Gelonin-MAb (XOMA Ltd); DTPA-BrE-3 (Coulter Corp); MG-132 (LeukoSite Inc);

NOVOMAb-G2 (Novopharm Biotech Inc); E-7070 (Eisai Co Ltd); C-1311

(University of Bradford); staurosporine (Kitasato Institute); Il-2 gene

therapy (cancer) (Sidney Kimmel Cancer Center); albendazole (Kline

Beecham plc); lovastatin (Merck & Co Inc); celecoxib (GD Searle & Co);

tarasentan (Abbott International Ltd); exisulind (Cell Pathways Inc); CD-437

(CIRD Galderma); phenylbutyrate (University of Virginia); UFT (Taiho

Pharmaceutical Co Ltd); TLC-ELL-12 (The Liposome Company Inc); beta-3

adrenergic (human) receptor (s Hopkins University); NU/ICRF-505

(Imperial Cancer Research Technology Ltd); BBR-3576 (Boehringer Mannheim

GmbH); dihydroxycalcitriol (University of Pittsburgh); anti-bcl-2

oligonucleotides (MD Cancer Center); scytonemin (University of

Oregon); gene therapy (cancer), Glaxo Wellcome (Glaxo Wellcome plc); gene

therapy (cancer), Oxford BioMedica (Oxford BioMedica plc); PD-098059

(Parke- & Co); MS-325 (EPIX Medical Inc); NSC-649488 (University of

Auckland); ABX-EGF (Abgenix Inc); PD-158780 (Parke- & Co Ltd);

recombinant adenoviral vectors (Institut Gustave Roussy); gemfibrozil

(Warner-Lambert Co); VNP-20009 (Vion Pharmaceuticals Inc); OGT-719 (Oxford

GlycoSciences plc); epirubicin (Pharmacia & Upjohn Inc); BNP-7787

(BioNumerik Pharmaceuticals Inc); AE-941 (AEterna Laboratories Inc);

(-)-epigallocatechin gallate (National Institutes of Health Japan);

decitabine (Pharmachemie BV); Contortrostatin (University of Southern

California); CPC-405 (Questcor Pharmaceuticals Inc); Apigenin (Kyowa Hakko

Kogyo Co Ltd); kareniticin (BioNumerik Pharmaceuticals Inc); TAS-103 (Taiho

Pharmaceutical Co Ltd); KT-5720 (Kyowa Hakko Kogyo Co Ltd); anticancer

agents (University of Illinois); rubitecan (Stehlin Foundation For Cancer

Research); D-609 (Tanabe Research Laboratories); HSPPC-96 (Mount Sinai

School of Medicine); emfilermin (AMRAD Corp Ltd); AG-879 (SUGEN Inc);

PD-090560 series (Parke- & Co); Endostatin (Children's Hospital of

Boston); Maspin (Dana-Farber Cancer Institute Inc); gene therapy (melanoma)

(Genzyme Molecular Oncology); 2-methoxyestradiol (Harvard University);

melanoma vaccine ( Wayne Cancer Institute); TEMPOL (US Department of

Health & Human Services); antitumor nucleosides (Hokkaido University);

Ukrain (Ukranian Anti-Cancer Institute); vapreotide (Debiopharm SA);

BMS-275291 (Celltech Group plc); Super-LEU-DOX (Coulter Pharmaceutical Inc);

TER-199 (Telik Inc); VUF-5000 (Vrije Universiteit); IMC-1C11 (ImClone

Systems Inc); huN901-DM1 (ImmunoGen Inc); Met TK antagonist (SUGEN Inc);

melanoma vaccine, Sloan-Kettering (Memorial Sloan-Kettering Cancer Center);

LY-355703 (Eli Lilly & Co); BBR-3464 (Boehringer Mannheim Italia SpA);

tgDCC-E1A (Targeted Genetics Corp); vinflunine (Pierre Fabre SA);

combretastatin A4 prodrug (Arizona State University); arzoxifene (Eli Lilly

& Co); JTE-522 (Japan Tobacco Inc); tezosentan (F Hoffmann-La Roche Ltd);

D-24241 (ASTA Medica AG); G-207 virus construct (NeuroVir Inc); CN-706

(Calydon Inc); CGS-24592 (Novartis AG); imexon (AmpliMed Corp); TRP-1/TRP-2

(National Institutes of Health); stearyl-Nle-VIP (Fujimoto Seiyaku Co Ltd);

SR-45023A (Symphar SA); ODN-2009 (University Hospital Zurich); LDP-341

(LeukoSite Inc); peptides (anticancer), (University of British Columbia);

PI-88 (Progen Industries Ltd); PARP inhibitors (Agouron Pharmaceuticals

Inc); INGN-221 (Introgen Therapeutics Inc); NLCQ-1 (ton Hospital Corp);

O6-benzylguanine (National Cancer Institute); NSC-330507 (University of

land); SC-72115 (GD Searle & Co); VE-cadherin-2 antagonists,

ImClone/ Negri (ImClone Systems Inc); NU-3076 (The University of

Newcastle Upon Tyne); U-0126 (DuPont Pharmaceuticals Co); NSC-314622

(National Cancer Institute); AG-1478 (University of California-San Diego

Medical Center); IDN-5109 (Indena SpA); ribozyme (VEGFr), Ribozyme/Chiron

(Ribozyme Pharmaceuticals Inc); CHS-828 (Leo Pharmaceutical Products Ltd

A/S); SBAS2 (Kline Beecham plc); K-ras ribozyme therapy (cancer)

(Berlex Biosciences); HX-600 (Nikken Chemicals Co Ltd); progenipoietin G (GD

Searle & Co); immunoliposomes (breast cancer) (University of California San

Francisco); mda-7 gene, Univ Columbia/GenQuest/Introgen (Columbia

University); Sch-66336 (Schering-Plough Research Institute); Fibrocaps

(Andaris Ltd); TRAIL/Apo2L, Genentech/Immunex (Immunex Corp); curacin A

(University of Pittsburgh); HSV gene therapy, GenVec (GenVec Inc); vaccines

(cancer), Onyvax (Onyvax Ltd); MIBG (Vrije Universiteit); anhydrovinblastine

(IGT Pharma Inc); CAPE, Strang Cancer Prevention Center (Strang Cancer

Prevention Center); endoglin MAbs, Roswell Park Cancer Institute (Roswell

Park Cancer Institute); suberanilohydroxamic acid (Memorial Sloan-Kettering

Cancer Center); plasminogen kringle 5, Abbott (Abbott Laboratories);

androgen synthesis inhibitors, University of land (University of

land); NLCPQ-1 (ton Hospital Corp); ODN-83 (University of Western

Ontario); LMB-2, NIH (National Cancer Institute); JBT-3002 (MD

Cancer Center); L-779450 (Merck & Co Inc); PD-0183805 (Parke- & Co);

mammastatin (Biotherapies Inc); NX-211 (Glaxo Wellcome plc); DTI-015 (Direct

Therapeutics Inc); MAb-81C6 (Duke University); Globo-H-KLH, Memorial

Sloan-Kettering (Memorial Sloan-Kettering Cancer Center); fucosyl-GM1-KLH,

Sloan-Kettering (Memorial Sloan-Kettering Cancer Center); DT388-GM-CSF, Univ

South Carolina Medical (University of South Carolina); 90Y-CC49 mAb,

University of Alabama (University of Alabama at Birmingham); 13-cis-retinoic

acid, UCLA (University of California San Diego); troxacitabine (BioChem

Therapeutic Inc); Pentacea (IBC Pharmaceuticals LLC); chemotherapy (cancer),

Enzacta (Enzacta Ltd); NU-2058 (The University of Newcastle Upon Tyne);

discodermolide (Harbor Branch Oceanographic Institute Inc); AdCMV.Y28, RPR

Gencell (RPR Gencell); 5F-203 (University of Nottingham); Cpd-5 (University

of Pittsburgh Cancer Institute); INXC-6295 (Inex Pharmaceuticals Corp);

GPI-0100 (Galenica Pharmaceuticals Inc); CEP-701 (Cephalon Inc); AG-2037

(Agouron Pharmaceuticals Inc); CGP-79807 (Novartis AG); WR-1065 (University

of Utah); roscovitine, Fox Chase (Fox Chase Cancer Center); Ad-IL-2,

Transgene (Transgene SA); TG-1031 (Transgene SA); CP-1 (Nortran

Pharmaceuticals Inc); ILX-23-7553 (F Hoffmann-La Roche Ltd); protein kinase

inhibitors, Kinetix (Kinetix Pharmaceuticals Inc); D-24851 (ASTA Medica AG);

SU-6668 (SUGEN Inc); CP-248 (Cell Pathways Inc); ONYX-838 (ONYX

Pharmaceuticals Inc); fusion-protein-directed IL-2 therapy, Scripps/Lexigen

(Scripps Research Institute); CP-461 (Cell Pathways Inc); R-101933 (Janssen

Pharmaceutica NV); GTI-2040 (Lorus Therapeutics Inc); IL-18 cancer therapy,

Kline Beecham (Hayashibara Biochemical Laboratories Inc); AdWTp53

transduction, NCI (National Cancer Institute); GP-100/GM-CSF melanoma

vaccine, University of Wisconsin (University of Wisconsin-Madison); anti-CEA

designer T cells, Beth Israel (Beth Israel Deaconess Medical Center);

caspase inhibitors, Aventis (Aventis Pharma AG); OC-144-093 (Ontogen Corp);

F-11782 (Pierre Fabre SA); methioninase + methioninase gene, Anticancer

(AntiCancer Inc); NB-1011 (NewBiotics Inc); adenoviral vector (prostate

tumor), MUSC (Medical University of South Carolina); RP-527 (Resolution

Pharmaceuticals Inc); T-900607 (Tularik Inc); A-007 analogs, Innsbruck

University (University of Innsbruck); TAS-106 (Taiho Pharmaceutical Co Ltd);

PNU-166196 (Pharmacia & Upjohn SpA); CCI-779 (Wyeth-Ayerst Research); A-6

(Angstrom Pharmaceuticals Inc); PNU-159548 (Pharmacia & Upjohn Inc);

®-flurbiprofen (Loma University Medical Center); HER2 antagonists,

SBI (Structural Bioinformatics Inc); tetrocarcin A (Kyowa Hakko Kogyo Co

Ltd); SR-271425 (Sanofi-Synthelabo); gnidimacrin (National Cancer Center);

A-105972 (Abbott Laboratories); ISIS-15999 (Isis Pharmaceuticals Inc);

NF-062 (University of Bonn); BMS-184476 (Bristol-Myers Squibb Co); BN-80915

(Beaufour-Ipsen); R-116010 (Janssen Research Foundation Worldwide); cTNF,

Cytimmune Sciences (Cytimmune Sciences Inc); recombinant mistletoe lectin

(University of Freiburg (Tumor Biology Center)); cancer therapy (reovirus),

Oncolytics (Oncolytics Biotech Inc); TNP-470 (Takeda Chemical Industries

Ltd); BGP-15 (University Medical School of Pecs); mammaglobin vaccine,

Corixa (Washington University); alsterpaullone (National Cancer Institute);

amifostine (US Bioscience Inc); inhaled doxorubicin, (BPT Battelle Pulmonary

Therapeutics); CV-787 (Calydon Inc); angiogenesis inhibitors,

(Convergence/Beth Israel Deaconess Medical Center); NM-3 (Convergence

Pharmaceuticals Inc); aphidicolin glycinate (Zeneca Group plc);

azidodideoxyguanosine (Medivir AB); ONO-8711 (Ono Pharmaceutical Co Ltd);

batimastat (British Biotech plc); G-3139 (Genta Inc); SC-1

(Julius-Maximilians-Universitat Wurzburg); DB-67 (University of Pittsburgh);

ZD-6126 (Angiogene Pharmaceuticals Ltd); ZD-6474 (AstraZeneca plc); arsenic

trioxide, (Cell Therapeutics PolaRx Biopharmaceuticals Inc); CDDO, MD

/Dartmouth College (MD Cancer Center); LPD vectors,

Targeted Genetics/University of Pittsburgh (University of Pittsburgh);

piroxicam cyclodextrin (Chiesi Farmaceutici SpA); fumagillin analogs, Chong

Kun Dang (Chong Kun Dang Corp); abciximab (Centocor Inc); zoledronic acid

(Novartis AG); sardomozide (Novartis AG); letrozole (Novartis AG);

BAY-38-3441 (Bayer AG); TXD-258 (Aventis Pharma AG); CI-994 (Parke- &

Co); BMS-265246 (Bristol-Myers Squibb Co); Anvirzel (Ozelle Pharmaceuticals

Inc); irinotecan (Yakult Honsha KK); troglitazone (Sankyo Co Ltd); fadrozole

(Novartis AG); fenretinide (McNeil Pharmaceuticals Inc); fialuridine

(Oclassen Pharmaceuticals Inc); finasteride (Merck & Co Inc); gemcitabine

(Eli Lilly & Co); elacridar (Glaxo Wellcome plc); TRP-1 protein vaccine,

ImClone (ImClone Systems Inc); fulvestrant (AstraZeneca plc); ICI-245991

(Zeneca Group plc); raltitrexed (AstraZeneca plc); flavopiridol (National

Cancer Institute); lactacystin (Yamanouchi Pharmaceutical Co Ltd);

lometrexol (Eli Lilly & Co); losoxantrone (Parke- & Co); LY-231514 (Eli

Lilly & Co); MDL-101731 (Aventis Pharmaceuticals); mifepristone (Aventis

Pharma AG); MK-886 (Merck & Co Inc); onapristone (Schering AG); PD-128763

(Parke- & Co); sirolimus (Wyeth-Ayerst Laboratories); SB-209763

(Scotgen Biopharmaceuticals Inc); tirapazamine (Stanford University); QS-21

(Aquila Biopharmaceuticals Inc); temozolomide (The University of Aston In

Birmingham); tiazofurin (ICN Pharmaceuticals Inc); TLC-D-99 (The Liposome

Company Inc); PKI-166 (Novartis AG); picibanil (Chugai Pharmaceutical Co

Ltd); PAM4 (Merck & Co Inc); nolatrexed (Agouron Pharmaceuticals Inc);

GL-331 (University of North Carolina); safingol (Sphinx Pharmaceuticals

Corp); GW-1843 (Glaxo Wellcome plc); PSC-833 (Novartis AG); bryostatin-1

(Arizona State University); eflornithine (Aventis Pharma AG); doxifluridine

(Nippon Roche KK); oltipraz (Rhone-Poulenc SA); acetyl-L-carnitine

(Sigma-Tau Ind Farm Riunite SpA); aldesleukin (Chiron Therapeutics);

Cardiolite (DuPont Pharmaceuticals Co); trastuzumab (Genentech Inc);

tocladesine (ICN Pharmaceuticals Inc); bexarotene (Ligand Pharmaceuticals

Inc); UCN-01 (Kyowa Hakko Kogyo Co Ltd); rituximab (IDEC Pharmaceuticals

Corp); adefovir (Rega Institute for Biomedical Research); prinomastat

(Agouron Pharmaceuticals Inc); AD-198 (Anthra Pharmaceuticals Inc); XK-469

(DuPont Pharmaceuticals Co); ZD-9331 (AstraZeneca plc); KW-2170 (Kyowa Hakko

Kogyo Co Ltd); interleukin-2 gene therapy, St Jude/Baylor (St Jude

Children`s Research Hospital); 3F8 (Genetics Institute Inc); edodekin alfa

(Genetics Institute Inc); L-651582 (Merck & Co Inc); glufosfamide (ASTA

Medica AG); ISIS-5132 (Isis Pharmaceuticals Inc); ISIS-4189 (Isis

Pharmaceuticals Inc); dexrazoxane (Imperial Cancer Research Technology Ltd);

INGN-201 (Introgen Therapeutics Inc); ICI-164384 (Zeneca Group plc);

BMS-214662 (Bristol-Myers Squibb Co); TA-HPV (Cancer Research Campaign

Technology Ltd); EB-1089 (Leo Pharmaceutical Products Ltd A/S);

dolastatin-10 (National Cancer Institute); TT-232 (BioSignal Inc); Doxil

(ALZA Corp); CT-2584 (Cell Therapeutics Inc); FR-901228 (Fujisawa

Pharmaceutical Co Ltd); NS-398 (Taisho Pharmaceutical Co Ltd); LY-294002

(Eli Lilly & Co); TER-286 (Telik Inc); marimastat (British Biotech plc);

LY-335979 (Roche Bioscience); MMI-270 (Novartis AG); RMP-7 (Alkermes Inc);

AG-555 (Hebrew University of Jerusalem); cariporide (Aventis Pharma AG);

Sch-58500 (Canji Inc); irofulven (MGI Pharma Inc); OctreoScan (Sandoz AG);

rosiglitazone (Kline Beecham plc); squalamine ( Magainin

Pharmaceuticals Inc); ET-743 (University of Illinois); dehydrodidemnin B

(Pharma Mar SA); kahalalide F (Pharma Mar SA); PTK-787 (Novartis AG); Gd-Tex

(Pharmacyclics Inc); lutetium texaphyrin (Pharmacyclics Inc); tretinoin,

Roche (Roche Holdings Inc); curcumin (Central Drug Research Institute);

trimidox (Molecules for Health); 9-aminocamptothecin (Research Triangle

Institute); CM-101( CarboMed Inc); PT-523 (Dana-Farber Cancer Institute

Inc); diethylnorspermine (University of Florida); Didox (Molecules for

Health); L-744832 (Merck & Co Inc); AC-9301 (AntiCancer Inc); nilutamide

(Aventis Pharma AG); vaccine (colon cancer), IRC/SKCC (Immune Response

Corp); FTI-276 (University of Pittsburgh); FTI-277 (University of

Pittsburgh); C-1027 (Taiho Pharmaceutical Co Ltd); B-956 (Eisai Co Ltd);

IntraDose (Matrix Pharmaceutical Inc) [364437].

Go to more American Association for Cancer Research 91st annual meeting

reports now

The meetings service of Current Drugs Ltd provides comprehensive coverage

of a wide range of meetings important to the pharmaceutical industry. All

relevant major international and smaller national scientific meetings are

covered. Meeting reports are available in the Investigational Drugs

database. For further information on the IDdb click here:

November 4, 2000